VRTX Vertex Pharmaceuticals Earnings and EPS analysis

EPS in 2025 (TTM): -$3.82

Last Report Period Date: Mar 31, 2025

As of June 2025, VRTX's current EPS stands at -$3.82, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of -$2.08, which marks a drop compared to its EPS of $14.05 in 2023. VRTX reported an EPS of $2.52 for the quarterly report ending on Mar 31, 2025.

VRTX earnings history

Historical annual and quarterly earnings per share (EPS) data for Vertex Pharmaceuticals

EPS (TTM)

-$3.82

EPS Growth YoY (Quarterly)

-40.8%

EPS (Quarterly)

$2.52

EPS Growth (Quarterly)

-28.6%

For 2024, Vertex Pharmaceuticals's EPS was -$2.08, a drop of 114.8% from $14.05 in 2023. For the fiscal quarter that ended on Mar 31, 2025, the per-share earnings was $2.52, showing a 40.8% decrease from the same quarter last year. For the twelve months ending March 2025, the EPS is -$3.82. For the year 2023, the yearly earnings per share was $14.05, marking an increase of 8.3% from 2022.

VRTX EPS growth

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-40.8%

EPS growth YoY

-114.8%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

During the last 12 months, Vertex Pharmaceuticals has seen an EPS growth of -40.8% (YoY, quarterly).

VRTX Earnings Waterfall

Breakdown of revenue, profit and net income for Vertex Pharmaceuticals

VRTX Earnings vs Peers

What are the earnings of VRTX compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
MRK Merck & Co Inc	11.46	4,728.6%	9.4%	12%
JNJ Johnson & Johnson	16.86	-57.9%	-9.7%	0.4%
BMY Bristol Myers Squibb Co	17.46	-213.7%	N/A	N/A
GILD Gilead Sciences Inc	23.17	-91.6%	-57.5%	-38.3%
ABBV AbbVie Inc	79.1	-12.1%	-28.2%	-14.7%
ENTA Enanta Pharmaceuticals Inc	N/A	14.1%	N/A	N/A
VRTX Vertex Pharmaceuticals Inc	N/A	-114.8%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.